Payment overview · 2025
General Payments
$2,677.65
35 reported records · 6 companies
Healthcare provider profile · identity verified
Roberto David Alvarez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · AIBONITO, PR · NPI 1225071467
Verified facts
What the public records show
CMS Open Payments records show Roberto David Alvarez, M.D. received $2,677.65 in general payments during 2025 across 35 reported records.
ABBVIE INC. accounted for 76.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Benlysta, Enbrel, Rinvoq.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 271 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Enbrel by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Prolia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BENLYSTA as an associated drug or biological on 19884 records involving 5034 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Benlysta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $2,037.39 | 76.1% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $202.60 | 7.6% | 9 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $155.67 | 5.8% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $127.48 | 4.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $94.86 | 3.5% | 5 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $59.65 | 2.2% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,820.00 | 3 |
| Food and Beverage | $857.65 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $2,037.39 | 9 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $155.67 | 8 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $127.48 | 2 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $110.50 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $110.50 | 5 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $94.86 | 5 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $92.10 | 4 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $92.10 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $67.06 | 3 | 2025 |
Source payment records
|
|||||
| HADLIMA Normalized: hadlima |
Drug | Organon LLC | $59.65 | 2 | 2025 |
Source payment records
|
|||||
| RENFLEXIS Normalized: renflexis |
Drug | Organon LLC | $59.65 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BENLYSTA benlysta |
2025 | Benlysta | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ENBREL enbrel |
2025 | Enbrel | 2024 | 126 | exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 191 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
191 | 27 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
271 | 57 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
126 | 21 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
112 | 88 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | BENLYSTA open payments reported associated product |
CMS Open Payments — General Payments 19884 supporting records · 5034 recipient NPIs · example record 1190332353 |
Benlysta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 5493 | 1095 |
| Tizanidine Hcl | Tizanidine Hcl | 3043 | 718 |
| Meloxicam | Meloxicam | 3024 | 695 |
| Methotrexate | Methotrexate Sodium | 2601 | 445 |
| Baclofen | Baclofen | 2293 | 471 |
| Prednisone | Prednisone | 1506 | 415 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 1376 | 245 |
| Famotidine | Famotidine | 1366 | 306 |
| Sulfasalazine | Sulfasalazine | 1222 | 248 |
| Amitriptyline Hcl | Amitriptyline Hcl | 990 | 187 |
| Nabumetone | Nabumetone | 853 | 179 |
| Alendronate Sodium | Alendronate Sodium | 738 | 166 |
| Leflunomide | Leflunomide | 651 | 129 |
| Duloxetine Hcl | Duloxetine Hcl | 433 | 104 |
| Pregabalin | Pregabalin | 402 | 103 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 395 | 72 |
| Omeprazole | Omeprazole | 392 | 95 |
| Diclofenac Sodium Er | Diclofenac Sodium | 385 | 100 |
| Sulindac | Sulindac | 363 | 71 |
| Tramadol Hcl | Tramadol Hcl | 304 | 152 |
| Pantoprazole Sodium | Pantoprazole Sodium | 300 | 67 |
| Hadlima(Cf) Pushtouch | Adalimumab-Bwwd | 283 | 47 |
| Synthroid | Levothyroxine Sodium | 271 | 57 |
| Allopurinol | Allopurinol | 270 | 55 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 223 | 85 |
| Naproxen | Naproxen | 220 | 46 |
| Colchicine | Colchicine | 210 | 54 |
| Diclofenac Sodium | Diclofenac Sodium | 201 | 59 |
| Rinvoq | Upadacitinib | 191 | 27 |
| Atorvastatin Calcium | Atorvastatin Calcium | 161 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 161 | 44 |
| Humira(Cf) | Adalimumab | 148 | 20 |
| Enbrel Sureclick | Etanercept | 146 | 17 |
| Losartan Potassium | Losartan Potassium | 138 | 35 |
| Metformin Hcl | Metformin Hcl | 135 | 36 |
| Humira(Cf) Pen | Adalimumab | 130 | 19 |
| Enbrel | Etanercept | 126 | 21 |
| Sucralfate | Sucralfate | 124 | 35 |
| Diclofenac Potassium | Diclofenac Potassium | 119 | 26 |
| Simvastatin | Simvastatin | 119 | 29 |
| Folic Acid | Folic Acid | 113 | 23 |
| Prolia | Denosumab | 112 | 88 |
| Risedronate Sodium | Risedronate Sodium | 105 | 21 |
| Raloxifene Hcl | Raloxifene Hcl | 103 | 24 |
| Celecoxib | Celecoxib | 101 | 17 |
| Amlodipine Besylate | Amlodipine Besylate | 98 | 24 |
| Clonazepam | Clonazepam | 94 | 27 |
| Montelukast Sodium | Montelukast Sodium | 91 | 24 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 90 | 24 |
| Etodolac | Etodolac | 90 | 19 |
| Lisinopril | Lisinopril | 90 | 26 |
| Levothyroxine Sodium | Levothyroxine Sodium | 82 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 24 |
| Ketoconazole | Ketoconazole | 65 | 24 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 65 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 64 | 24 |
| Temazepam | Temazepam | 64 | 19 |
| Orencia | Abatacept | 60 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 57 | suppressed |
| Amjevita(Cf) Autoinjector | Adalimumab-Atto | 52 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 52 | 18 |
| Lansoprazole | Lansoprazole | 51 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 49 | 14 |
| Ibuprofen | Ibuprofen | 47 | 18 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 46 | 17 |
| Amantadine | Amantadine Hcl | 44 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 44 | suppressed |
| Topiramate | Topiramate | 43 | suppressed |
| Benlysta | Belimumab | 40 | suppressed |
| Orencia Clickject | Abatacept | 40 | suppressed |
| Methylprednisolone | Methylprednisolone | 39 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 37 | suppressed |
| Cosentyx Unoready Pen | Secukinumab | 36 | suppressed |
| Hadlima(Cf) | Adalimumab-Bwwd | 36 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 35 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 32 | suppressed |
| Savella | Milnacipran Hcl | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 30 |
| Enbrel Mini | Etanercept | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 26 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 25 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 25 | suppressed |
| Cyltezo(Cf) Pen | Adalimumab-Adbm | 24 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 14 |
| Mupirocin | Mupirocin | 21 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | 17 |
| Azithromycin | Azithromycin | 20 | 19 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 19 | suppressed |
| Carvedilol | Carvedilol | 18 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 18 | suppressed |
| Febuxostat | Febuxostat | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Cholestyramine Light | Cholestyramine | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 15 |
| Lidocaine | Lidocaine | 16 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 16 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 15 | suppressed |
| Ursodiol | Ursodiol | 15 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Cyltezo(Cf) | Adalimumab-Adbm | 13 | suppressed |
| Eliquis | Apixaban | 13 | suppressed |
| Estazolam | Estazolam | 13 | suppressed |
| Forteo | Teriparatide | 13 | suppressed |
| Kevzara | Sarilumab | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Teriparatide | Teriparatide | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 11 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Cosentyx (2 Syringes) | Secukinumab | 11 | suppressed |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 11 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Furosemide | Furosemide | 11 | suppressed |
| Levoxyl | Levothyroxine Sodium | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,677.65 · 35 records | ABBVIE INC. | BENLYSTA, COSENTYX, ENBREL, EVENITY, HADLIMA, KRYSTEXXA, OTEZLA, RENFLEXIS, RINVOQ, SAPHNELO, TAVNEOS | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Benlysta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error